Ken Griffin
FOMX

Ken Griffin’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Ken Griffin’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,400
Closed -$146K – 10116
2018
Q3 		$146K Buy
+25,400
New +$145K ﹤0.01% 8415
2017
Q2 		– Sell
-31,100
Closed -$154K – 8346
2017
Q1 		$154K Buy
+31,100
New +$299K ﹤0.01% 6674

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Ken Griffin's FOMX Position: Q4 2019 in Review

Ken Griffin sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q4 2019, closing a stake of 14,753 shares — an estimated $45K sold.

Ken Griffin first reported a position in FOMX in Q4 2016 and held it in 7 quarters. The position peaked at $3.1M in Q3 2018. 65 funds tracked by Wall St. Rank hold FOMX as of Q4 2019.

  • Ken Griffin reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q4 2019 after selling out during the quarter.
  • Ken Griffin sold 14,753 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q4 2019, an estimated $45K.
  • Ken Griffin first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2016 and held it in 7 quarters.
  • Ken Griffin's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $3.1M in Q3 2018.
  • 65 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q4 2019.

Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.